IQAI.F Stock Overview
Through its subsidiaries, develops software applications for the healthcare industry in Jersey, the United Kingdom, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IQ-AI Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.015 |
| 52 Week High | UK£0.055 |
| 52 Week Low | UK£0.015 |
| Beta | 2.91 |
| 1 Month Change | -11.76% |
| 3 Month Change | -48.28% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| IQAI.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -11.8% | 3.2% | 1.2% |
| 1Y | n/a | -2.8% | 27.7% |
Return vs Industry: Insufficient data to determine how IQAI.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how IQAI.F performed against the US Market.
Price Volatility
| IQAI.F volatility | |
|---|---|
| IQAI.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IQAI.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IQAI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Trevor Brown | www.imagingbiometrics.com/iq-ai-ltd |
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey, the United Kingdom, and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and IB StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.
IQ-AI Limited Fundamentals Summary
| IQAI.F fundamental statistics | |
|---|---|
| Market cap | US$3.95m |
| Earnings (TTM) | -US$793.11k |
| Revenue (TTM) | US$774.77k |
5.1x
P/S Ratio-5.0x
P/E RatioIs IQAI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQAI.F income statement (TTM) | |
|---|---|
| Revenue | UK£609.39k |
| Cost of Revenue | UK£11.64k |
| Gross Profit | UK£597.75k |
| Other Expenses | UK£1.22m |
| Earnings | -UK£623.82k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0028 |
| Gross Margin | 98.09% |
| Net Profit Margin | -102.37% |
| Debt/Equity Ratio | 0% |
How did IQAI.F perform over the long term?
See historical performance and comparison